Youcare Pharmaceutical's (SHA:688658) unit, Beijing Youcare Kechuang Pharmaceutical Technology, received approval from the U.S. Food and Drug Administration to proceed with the clinical trial of YKYY033 injection, according to a Shanghai bourse filing on Thursday.
The drug will be tested as a prevention and treatment for arterial and venous thrombosis.
The Chinese pharmaceutical company's shares rose 1% during the afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.